董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ryan M. Confer | 男 | President, Chief Executive Officer & Chief Financial Officer and Director | 44 | 127.02万美元 | 未持股 | 2025-08-15 |
| William R. Wilson, Jr. | 男 | Director | 75 | 14.72万美元 | 未持股 | 2025-08-15 |
| Jose Antonio Moreno Toscano | 男 | Director and non-executive Chairman | 52 | 15.16万美元 | 未持股 | 2025-08-15 |
| Brent M. Longnecker | 男 | Director | 69 | 15.16万美元 | 未持股 | 2025-08-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark S. Berger | 男 | Chief Medical Officer | 70 | 未披露 | 未持股 | 2025-08-15 |
| Ryan M. Confer | 男 | President, Chief Executive Officer & Chief Financial Officer and Director | 44 | 127.02万美元 | 未持股 | 2025-08-15 |
董事简历
中英对照 | 中文 | 英文- Ryan M. Confer
-
RyanM.Confer自2016年9月起担任我们的首席财务官。从2013年12月到2016年9月，他曾担任我们的首席运营和财务官，以及我们的业务经理（从2011年6月到2013年12月）。Confer自2009年公司成立起担任多个战略、运营和财务职位，包括Confer Capital，Inc.顾问和员工。Confer先生还曾担任德克萨斯大学奥斯汀分校IC2研究所（University of Texas at Austin’；S IC2Institute）的国际业务开发顾问，在那里他专注于评估国内和国际市场上适用于与该大学相关的技术孵化器计划的新兴技术的商业化潜力。Confer先生拥有宾夕法尼亚布鲁姆斯堡大学（Bloomsburg University of Pennsylvania）的金融和法律研究学士学位，以及得克萨斯大学奥斯汀分校（University of Texas at Austin）麦康姆斯商学院（McCombs School of Business）的技术商业化硕士学位。
Ryan M. Confer,also currently serves as Genprex, Inc. Chief Financial Officer, a position he has held since September 2016. From December 2013 through September 2016, he served as Genprex, Inc. Chief Operating and Financial Officer, and from June 2011 to December 2013 as Genprex, Inc. Business Manager. Mr. Confer has served Genprex, Inc. in a variety of strategic, operations, and finance capacities since Genprex, Inc. inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as Vice President of Customer Experience and then later as Vice President of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin's IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin. - RyanM.Confer自2016年9月起担任我们的首席财务官。从2013年12月到2016年9月，他曾担任我们的首席运营和财务官，以及我们的业务经理（从2011年6月到2013年12月）。Confer自2009年公司成立起担任多个战略、运营和财务职位，包括Confer Capital，Inc.顾问和员工。Confer先生还曾担任德克萨斯大学奥斯汀分校IC2研究所（University of Texas at Austin’；S IC2Institute）的国际业务开发顾问，在那里他专注于评估国内和国际市场上适用于与该大学相关的技术孵化器计划的新兴技术的商业化潜力。Confer先生拥有宾夕法尼亚布鲁姆斯堡大学（Bloomsburg University of Pennsylvania）的金融和法律研究学士学位，以及得克萨斯大学奥斯汀分校（University of Texas at Austin）麦康姆斯商学院（McCombs School of Business）的技术商业化硕士学位。
- Ryan M. Confer,also currently serves as Genprex, Inc. Chief Financial Officer, a position he has held since September 2016. From December 2013 through September 2016, he served as Genprex, Inc. Chief Operating and Financial Officer, and from June 2011 to December 2013 as Genprex, Inc. Business Manager. Mr. Confer has served Genprex, Inc. in a variety of strategic, operations, and finance capacities since Genprex, Inc. inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as Vice President of Customer Experience and then later as Vice President of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin's IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.
- William R. Wilson, Jr.
-
William R. Wilson，Jr.自2020年3月18日以来一直担任我们的董事会成员。2006年1月以来，他曾一直担任Wilson Land&Cattle公司（投资公司）的主席、总裁兼首席执行官。Wilson先生在医疗保健监管、生物技术、临床试验管理、养老院许可和监管、医师认证、证券、公司治理、合同和其他法律事务方面拥有超过40年的法律经验。Wilson先生是德克萨斯州律师协会的成员，并已被允许在美国德克萨斯州西区地方法院执业。Wilson先生曾担任德克萨斯州特拉维斯县第250地区法院的法官，在那里他主持民事诉讼，并担任德克萨斯州达拉斯县的助理地区检察官。Wilson先生拥有范德比尔特大学的理学学士学位和南卫理公会大学的法学博士学位。
William R. Wilson, Jr.,Since January 2006, he has served as Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co., an investment company. Mr. Wilson has more than 40 years of legal experience in health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, contractual and other legal matters. Mr. Wilson is a member of the State Bar of Texas and has been admitted to practice before the United States District Court for the Western District of Texas. Mr. Wilson previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, and as Assistant District Attorney for Dallas County, Texas. Mr. Wilson holds a Bachelor of Arts degree from Vanderbilt University and a JD degree from Southern Methodist University. - William R. Wilson，Jr.自2020年3月18日以来一直担任我们的董事会成员。2006年1月以来，他曾一直担任Wilson Land&Cattle公司（投资公司）的主席、总裁兼首席执行官。Wilson先生在医疗保健监管、生物技术、临床试验管理、养老院许可和监管、医师认证、证券、公司治理、合同和其他法律事务方面拥有超过40年的法律经验。Wilson先生是德克萨斯州律师协会的成员，并已被允许在美国德克萨斯州西区地方法院执业。Wilson先生曾担任德克萨斯州特拉维斯县第250地区法院的法官，在那里他主持民事诉讼，并担任德克萨斯州达拉斯县的助理地区检察官。Wilson先生拥有范德比尔特大学的理学学士学位和南卫理公会大学的法学博士学位。
- William R. Wilson, Jr.,Since January 2006, he has served as Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co., an investment company. Mr. Wilson has more than 40 years of legal experience in health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, contractual and other legal matters. Mr. Wilson is a member of the State Bar of Texas and has been admitted to practice before the United States District Court for the Western District of Texas. Mr. Wilson previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, and as Assistant District Attorney for Dallas County, Texas. Mr. Wilson holds a Bachelor of Arts degree from Vanderbilt University and a JD degree from Southern Methodist University.
- Jose Antonio Moreno Toscano
-
Jose AntonioMoreno Toscano自2020年3月18日起担任我们的董事会成员。自2018年4月以来，Moreno Toscano先生一直担任LFB USA Inc.的首席执行官，LFB USA Inc.是LFB Group的美国子公司，LFB Group是一家全球综合生物制药公司，致力于通过重组，血浆衍生和细胞治疗技术开发创新产品。从2017年7月至2018年3月，Moreno Toscano先生担任安全港合规和临床服务总裁，这是一家综合医疗服务提供商，致力于在初级保健办公室提供特种药品和辅助服务。从2016年7月至2018年9月，他还担任董事会成员。从2016年3月至2017年3月，Moreno Toscano先生担任Kompan Inc.的美洲首席执行官，该公司是Kompan A/S的美国子公司，是游乐场设备的全球领导者。从2006年3月到2016年3月，Moreno Toscano先生担任ALK-Abello Inc.的总裁，该公司是ALK-Abello A/S的美国子公司，该公司是一家制药公司，是过敏免疫疗法的全球领导者。任职ALK-Abello公司之前，他曾担任APplus A/S公司（汽车检测服务的市场领导者）的首席财务官，也曾担任Christian Hansen Holding A/S公司（制药制造和食品、饮料天然成分的生产商的全球领导者）的多种职务，膳食补充剂和农业产业。Moreno Toscano先生拥有西班牙穆尔西亚大学的法学硕士学位和巴黎国立庞茨和肖斯学院的国际金融和战略工商管理硕士学位。Moreno Toscano先生拥有全国公司董事协会NACD董事证书。
Jose Antonio Moreno Toscano,Since April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc., the US subsidiary of LFB Group, a global integrated biopharmaceutical company dedicated to developing innovative products through recombinant, plasma derived and cell therapy technology. From July 2017 to March 2018, Mr. Moreno Toscano served as President of Safe Harbor Compliance and Clinical Services, an integrated health care services provider dedicated to providing specialty pharmaceuticals and ancillary services in primary care offices, and from July 2016 to September 2018, he also served as a member of its board of directors. From March 2016 to March 2017, Mr. Moreno Toscano served as CEO, Americas, for Kompan Inc., a US subsidiary of Kompan A/S, a world leader in playground equipment. From March 2006 to March 2016, Mr. Moreno Toscano served as President of ALK-Abello Inc., a US subsidiary of ALK-Abello A/S, a pharmaceutical company that is a world leader in allergy immunotherapy. Prior to his tenure with ALK-Abello, Mr. Moreno Toscano was the Chief Financial Officer of Applus A/S, a market leader in automotive inspection services, and prior to Applus, he held several positions at Christian Hansen Holding A/S, a global leader in pharmaceutical manufacturing and producer of natural ingredients for the food, beverage, dietary supplement and agricultural industries. Mr. Moreno Toscano holds a Master's Degree in Law from the Universidad de Murcia in Spain and an MBA in International Finance and Strategy from the Ecole Nationale des Ponts et Chaussees in Paris. Mr. Moreno Toscano holds the National Association of Corporate Directors (NACD) Directorship CertificationTM. - Jose AntonioMoreno Toscano自2020年3月18日起担任我们的董事会成员。自2018年4月以来，Moreno Toscano先生一直担任LFB USA Inc.的首席执行官，LFB USA Inc.是LFB Group的美国子公司，LFB Group是一家全球综合生物制药公司，致力于通过重组，血浆衍生和细胞治疗技术开发创新产品。从2017年7月至2018年3月，Moreno Toscano先生担任安全港合规和临床服务总裁，这是一家综合医疗服务提供商，致力于在初级保健办公室提供特种药品和辅助服务。从2016年7月至2018年9月，他还担任董事会成员。从2016年3月至2017年3月，Moreno Toscano先生担任Kompan Inc.的美洲首席执行官，该公司是Kompan A/S的美国子公司，是游乐场设备的全球领导者。从2006年3月到2016年3月，Moreno Toscano先生担任ALK-Abello Inc.的总裁，该公司是ALK-Abello A/S的美国子公司，该公司是一家制药公司，是过敏免疫疗法的全球领导者。任职ALK-Abello公司之前，他曾担任APplus A/S公司（汽车检测服务的市场领导者）的首席财务官，也曾担任Christian Hansen Holding A/S公司（制药制造和食品、饮料天然成分的生产商的全球领导者）的多种职务，膳食补充剂和农业产业。Moreno Toscano先生拥有西班牙穆尔西亚大学的法学硕士学位和巴黎国立庞茨和肖斯学院的国际金融和战略工商管理硕士学位。Moreno Toscano先生拥有全国公司董事协会NACD董事证书。
- Jose Antonio Moreno Toscano,Since April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc., the US subsidiary of LFB Group, a global integrated biopharmaceutical company dedicated to developing innovative products through recombinant, plasma derived and cell therapy technology. From July 2017 to March 2018, Mr. Moreno Toscano served as President of Safe Harbor Compliance and Clinical Services, an integrated health care services provider dedicated to providing specialty pharmaceuticals and ancillary services in primary care offices, and from July 2016 to September 2018, he also served as a member of its board of directors. From March 2016 to March 2017, Mr. Moreno Toscano served as CEO, Americas, for Kompan Inc., a US subsidiary of Kompan A/S, a world leader in playground equipment. From March 2006 to March 2016, Mr. Moreno Toscano served as President of ALK-Abello Inc., a US subsidiary of ALK-Abello A/S, a pharmaceutical company that is a world leader in allergy immunotherapy. Prior to his tenure with ALK-Abello, Mr. Moreno Toscano was the Chief Financial Officer of Applus A/S, a market leader in automotive inspection services, and prior to Applus, he held several positions at Christian Hansen Holding A/S, a global leader in pharmaceutical manufacturing and producer of natural ingredients for the food, beverage, dietary supplement and agricultural industries. Mr. Moreno Toscano holds a Master's Degree in Law from the Universidad de Murcia in Spain and an MBA in International Finance and Strategy from the Ecole Nationale des Ponts et Chaussees in Paris. Mr. Moreno Toscano holds the National Association of Corporate Directors (NACD) Directorship CertificationTM.
- Brent M. Longnecker
-
Brent M. Longnecker，2007年以来曾是AmREIT董事，目前作为薪酬委员会主席。他还担任医疗服务公司董事和审计和薪酬委员会委员。自2003年以来他生担任Longnecker & Associates的总裁，一家高管薪酬和治理咨询公司。他从1999年6月至2003年担任资源咨询集团的总裁，资源连接公司执行副总裁。他拥有20多年的咨询经验，包括Deloitte & Touche绩效管理和薪酬咨询实践的国家Principal-In-Charge和德勤& 毕马威会计事务所的合伙人。他的咨询经验包括与房地产公司合作，包括上市公司在内的公司治理问题和资产的管理。他拥有工商管理学士学位，休斯顿大学的工商管理硕士学位。
Brent M. Longnecker,has been the Chairman and Chief Executive Officer of 1 Reputation, a strategy, executive compensation, and corporate governance consulting firm. From August 2003 to February 2022, Mr. Longnecker was Founder & CEO of Longnecker & Associates. From June 1999 to August 2003, Mr. Longnecker served as President of Resources Consulting Group, and Executive Vice President of Resources Connection. Mr. Longnecker has over 36 years of consulting experience, including as National Partner-In-Charge for the Performance Management and Compensation Consulting Practice of Deloitte & Touche and as partner at KPMG Peat Marwick. Mr. Longnecker has worked with companies globally including the industries of high tech, finance, service, manufacturing and more. He is a Board Fellow with the NACD and is a past board member. Mr. Longnecker holds Bachelor of Business Administration and MBA degrees from the University of Houston. He is a prolific author about executive compensation and corporate governance. - Brent M. Longnecker，2007年以来曾是AmREIT董事，目前作为薪酬委员会主席。他还担任医疗服务公司董事和审计和薪酬委员会委员。自2003年以来他生担任Longnecker & Associates的总裁，一家高管薪酬和治理咨询公司。他从1999年6月至2003年担任资源咨询集团的总裁，资源连接公司执行副总裁。他拥有20多年的咨询经验，包括Deloitte & Touche绩效管理和薪酬咨询实践的国家Principal-In-Charge和德勤& 毕马威会计事务所的合伙人。他的咨询经验包括与房地产公司合作，包括上市公司在内的公司治理问题和资产的管理。他拥有工商管理学士学位，休斯顿大学的工商管理硕士学位。
- Brent M. Longnecker,has been the Chairman and Chief Executive Officer of 1 Reputation, a strategy, executive compensation, and corporate governance consulting firm. From August 2003 to February 2022, Mr. Longnecker was Founder & CEO of Longnecker & Associates. From June 1999 to August 2003, Mr. Longnecker served as President of Resources Consulting Group, and Executive Vice President of Resources Connection. Mr. Longnecker has over 36 years of consulting experience, including as National Partner-In-Charge for the Performance Management and Compensation Consulting Practice of Deloitte & Touche and as partner at KPMG Peat Marwick. Mr. Longnecker has worked with companies globally including the industries of high tech, finance, service, manufacturing and more. He is a Board Fellow with the NACD and is a past board member. Mr. Longnecker holds Bachelor of Business Administration and MBA degrees from the University of Houston. He is a prolific author about executive compensation and corporate governance.
高管简历
中英对照 | 中文 | 英文- Mark S. Berger
MarkS.Berger自2017年1月以来一直担任我们的首席医疗官。2013年9月至2017年1月，Berger博士在Kadmon Corporation工作，高级副总裁，临床研究。在这个职位上，他负责新药开发的所有临床方面，包括设计和管理肿瘤适应症非小细胞肺癌和胶质母细胞瘤以及非肿瘤适应症（慢性移植物抗宿主病和多囊肾病）的临床试验。Berger博士在2011年6月至2013年9月担任Deciphera Pharmaceuticals（“；Deciphera”；）的首席医疗官后加入Kadmon。任职Deciphera公司之前，他曾担任Gemin X Pharmaceuticals公司（“；Gemin X”；）的临床开发Vice President，在那里他曾领导两种新型肿瘤药物的临床战略、设计和临床试验管理，其中包括Obatoclax公司（泛BCL-2抑制剂）。根据Obatoclax的随机2期临床试验结果，Gemin X于2011年3月被Cephalon收购，总对价为5.25亿美元，其中包括2.25亿美元的前期现金付款。在生物技术公司工作之前，Berger博士在两家全球制药公司担任要职。Berger博士此前曾担任GlaxoSmithKline肿瘤学药物开发中心的集团总监。在该职位上，Berger博士管理Tykerb（Lapatinib）在肺癌和乳腺癌的开发，在那里他设计并领导两个2期临床试验，然后计划并领导399名患者关键的3期试验，该试验导致FDA批准Tykerb在乳腺癌中的应用。此外，他管理Lapatinib Extended Access Program，该项目在全球范围内招募了超过4000名患者。Berger博士在惠氏研究公司（Wyeth Research）开始了他的药物开发职业生涯，在那里他领导了Mylotarg关键的2期试验的计划和执行，这是第一种抗体靶向化疗剂，靶向与Actimab-A类似的CD33。他在FDA’；s肿瘤药物咨询委员会会议上介绍了Mylotarg的临床数据，之后Mylotarg获得了FDA对复发AML患者的加速批准。Berger博士在卫斯理大学（Wesleyan University）获得生物学学士学位，并在弗吉尼亚大学医学院（University of Virginia School of Medicine）获得医学博士学位。他在宾夕法尼亚大学（University of Pennsylvania）获得血液肿瘤学奖学金，在那里他是医学助理教授，也是伦敦路德维希癌症研究所和帝国癌症研究基金（Imperial Cancer Research Fund）的研究员。Berger博士获得内科，血液学和医疗肿瘤学的董事会认证。
Mark S. Berger has been Chief Medical Officer since January 2017. From September 2013 to January 2017 Dr. Berger worked for Kadmon Corporation where he was senior vice president, clinical research. In this role he was responsible for all clinical aspects of new drug development including designing and managing clinical trials in oncology indications non-small cell lung cancer and glioblastoma and non-oncology indications (chronic graft versus host disease and polycystic kidney disease). Dr. Berger joined Kadmon after serving as chief medical officer of Deciphera Pharmaceuticals ("Deciphera") from June 2011 to September 2013. Prior to Deciphera, Dr. Berger was vice president for clinical development at Gemin X Pharmaceuticals ("Gemin X") where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax, a pan Bcl-2 inhibitor. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011 for a total consideration of $525 million including $225 million in an upfront cash payment. Before his work with biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as group director, medicine development centre-oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent and targeted CD33 similar to Actimab-A. He presented the Mylotarg clinical data at the FDA's Oncology Drug Advisory Committee meeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML. Dr. Berger has a B.A. in biology from Wesleyan University and received his M.D. from the University of Virginia School of Medicine. He did his Hematology-Oncology fellowship at the University of Pennsylvania where he was an Assistant Professor of Medicine, and also was a Research Fellow at the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology and medical oncology.- MarkS.Berger自2017年1月以来一直担任我们的首席医疗官。2013年9月至2017年1月，Berger博士在Kadmon Corporation工作，高级副总裁，临床研究。在这个职位上，他负责新药开发的所有临床方面，包括设计和管理肿瘤适应症非小细胞肺癌和胶质母细胞瘤以及非肿瘤适应症（慢性移植物抗宿主病和多囊肾病）的临床试验。Berger博士在2011年6月至2013年9月担任Deciphera Pharmaceuticals（“；Deciphera”；）的首席医疗官后加入Kadmon。任职Deciphera公司之前，他曾担任Gemin X Pharmaceuticals公司（“；Gemin X”；）的临床开发Vice President，在那里他曾领导两种新型肿瘤药物的临床战略、设计和临床试验管理，其中包括Obatoclax公司（泛BCL-2抑制剂）。根据Obatoclax的随机2期临床试验结果，Gemin X于2011年3月被Cephalon收购，总对价为5.25亿美元，其中包括2.25亿美元的前期现金付款。在生物技术公司工作之前，Berger博士在两家全球制药公司担任要职。Berger博士此前曾担任GlaxoSmithKline肿瘤学药物开发中心的集团总监。在该职位上，Berger博士管理Tykerb（Lapatinib）在肺癌和乳腺癌的开发，在那里他设计并领导两个2期临床试验，然后计划并领导399名患者关键的3期试验，该试验导致FDA批准Tykerb在乳腺癌中的应用。此外，他管理Lapatinib Extended Access Program，该项目在全球范围内招募了超过4000名患者。Berger博士在惠氏研究公司（Wyeth Research）开始了他的药物开发职业生涯，在那里他领导了Mylotarg关键的2期试验的计划和执行，这是第一种抗体靶向化疗剂，靶向与Actimab-A类似的CD33。他在FDA’；s肿瘤药物咨询委员会会议上介绍了Mylotarg的临床数据，之后Mylotarg获得了FDA对复发AML患者的加速批准。Berger博士在卫斯理大学（Wesleyan University）获得生物学学士学位，并在弗吉尼亚大学医学院（University of Virginia School of Medicine）获得医学博士学位。他在宾夕法尼亚大学（University of Pennsylvania）获得血液肿瘤学奖学金，在那里他是医学助理教授，也是伦敦路德维希癌症研究所和帝国癌症研究基金（Imperial Cancer Research Fund）的研究员。Berger博士获得内科，血液学和医疗肿瘤学的董事会认证。
- Mark S. Berger has been Chief Medical Officer since January 2017. From September 2013 to January 2017 Dr. Berger worked for Kadmon Corporation where he was senior vice president, clinical research. In this role he was responsible for all clinical aspects of new drug development including designing and managing clinical trials in oncology indications non-small cell lung cancer and glioblastoma and non-oncology indications (chronic graft versus host disease and polycystic kidney disease). Dr. Berger joined Kadmon after serving as chief medical officer of Deciphera Pharmaceuticals ("Deciphera") from June 2011 to September 2013. Prior to Deciphera, Dr. Berger was vice president for clinical development at Gemin X Pharmaceuticals ("Gemin X") where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax, a pan Bcl-2 inhibitor. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011 for a total consideration of $525 million including $225 million in an upfront cash payment. Before his work with biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as group director, medicine development centre-oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent and targeted CD33 similar to Actimab-A. He presented the Mylotarg clinical data at the FDA's Oncology Drug Advisory Committee meeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML. Dr. Berger has a B.A. in biology from Wesleyan University and received his M.D. from the University of Virginia School of Medicine. He did his Hematology-Oncology fellowship at the University of Pennsylvania where he was an Assistant Professor of Medicine, and also was a Research Fellow at the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology and medical oncology.
- Ryan M. Confer
RyanM.Confer自2016年9月起担任我们的首席财务官。从2013年12月到2016年9月，他曾担任我们的首席运营和财务官，以及我们的业务经理（从2011年6月到2013年12月）。Confer自2009年公司成立起担任多个战略、运营和财务职位，包括Confer Capital，Inc.顾问和员工。Confer先生还曾担任德克萨斯大学奥斯汀分校IC2研究所（University of Texas at Austin’；S IC2Institute）的国际业务开发顾问，在那里他专注于评估国内和国际市场上适用于与该大学相关的技术孵化器计划的新兴技术的商业化潜力。Confer先生拥有宾夕法尼亚布鲁姆斯堡大学（Bloomsburg University of Pennsylvania）的金融和法律研究学士学位，以及得克萨斯大学奥斯汀分校（University of Texas at Austin）麦康姆斯商学院（McCombs School of Business）的技术商业化硕士学位。
Ryan M. Confer,also currently serves as Genprex, Inc. Chief Financial Officer, a position he has held since September 2016. From December 2013 through September 2016, he served as Genprex, Inc. Chief Operating and Financial Officer, and from June 2011 to December 2013 as Genprex, Inc. Business Manager. Mr. Confer has served Genprex, Inc. in a variety of strategic, operations, and finance capacities since Genprex, Inc. inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as Vice President of Customer Experience and then later as Vice President of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin's IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.- RyanM.Confer自2016年9月起担任我们的首席财务官。从2013年12月到2016年9月，他曾担任我们的首席运营和财务官，以及我们的业务经理（从2011年6月到2013年12月）。Confer自2009年公司成立起担任多个战略、运营和财务职位，包括Confer Capital，Inc.顾问和员工。Confer先生还曾担任德克萨斯大学奥斯汀分校IC2研究所（University of Texas at Austin’；S IC2Institute）的国际业务开发顾问，在那里他专注于评估国内和国际市场上适用于与该大学相关的技术孵化器计划的新兴技术的商业化潜力。Confer先生拥有宾夕法尼亚布鲁姆斯堡大学（Bloomsburg University of Pennsylvania）的金融和法律研究学士学位，以及得克萨斯大学奥斯汀分校（University of Texas at Austin）麦康姆斯商学院（McCombs School of Business）的技术商业化硕士学位。
- Ryan M. Confer,also currently serves as Genprex, Inc. Chief Financial Officer, a position he has held since September 2016. From December 2013 through September 2016, he served as Genprex, Inc. Chief Operating and Financial Officer, and from June 2011 to December 2013 as Genprex, Inc. Business Manager. Mr. Confer has served Genprex, Inc. in a variety of strategic, operations, and finance capacities since Genprex, Inc. inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as Vice President of Customer Experience and then later as Vice President of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin's IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.